Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pankaj Seth is active.

Publication


Featured researches published by Pankaj Seth.


Nature Medicine | 2008

Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability

Christopher A. Jones; Nyall R. London; Haoyu Chen; Kye Won Park; Dominique Sauvaget; Rebecca A. Stockton; Joshua D. Wythe; Wonhee Suh; Frederic Larrieu-Lahargue; Yoh Suke Mukouyama; Per Lindblom; Pankaj Seth; Antonio E. Frias; Naoyuki Nishiya; Mark H. Ginsberg; Holger Gerhardt; Kang Zhang; Dean Y. Li

The angiogenic sprout has been compared to the growing axon, and indeed, many proteins direct pathfinding by both structures. The Roundabout (Robo) proteins are guidance receptors with well-established functions in the nervous system; however, their role in the mammalian vasculature remains ill defined. Here we show that an endothelial-specific Robo, Robo4, maintains vascular integrity. Activation of Robo4 by Slit2 inhibits vascular endothelial growth factor (VEGF)-165-induced migration, tube formation and permeability in vitro and VEGF-165-stimulated vascular leak in vivo by blocking Src family kinase activation. In mouse models of retinal and choroidal vascular disease, Slit2 inhibited angiogenesis and vascular leak, whereas deletion of Robo4 enhanced these pathologic processes. Our results define a previously unknown function for Robo receptors in stabilizing the vasculature and suggest that activating Robo4 may have broad therapeutic application in diseases characterized by excessive angiogenesis and/or vascular leak.


Wound Repair and Regeneration | 1999

Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice

Gurmel S. Sidhu; Haresh Mani; Jaya P. Gaddipati; Anoop K. Singh; Pankaj Seth; Krishna K. Banaudha; G. K. Patnaik; Radha K. Maheshwari

Tissue repair and wound healing are complex processes that involve inflammation, granulation and tissue remodeling. Interactions of different cells, extracellular matrix proteins and their receptors are involved in wound healing, and are mediated by cytokines and growth factors. Previous studies from our laboratory have shown that curcumin (diferuloylmethane), a natural product obtained from the rhizomes of Curcuma longa, enhanced cutaneous wound healing in rats and guinea pigs. In this study, we have evaluated the efficacy of curcumin treatment by oral and topical applications on impaired wound healing in diabetic rats and genetically diabetic mice using a full thickness cutaneous punch wound model. Wounds of animals treated with curcumin showed earlier re‐epithelialization, improved neovascularization, increased migration of various cells including dermal myofibroblasts, fibroblasts, and macrophages into the wound bed, and a higher collagen content. Immunohistochemical localization showed an increase in transforming growth factor‐β1 in curcumin‐treated wounds compared to controls. Enhanced transforming growth factor‐β1 mRNA expression in treated wounds was confirmed by in situ hybridization, and laser scan cytometry. A delay in the apoptosis patterns was seen in diabetic wounds compared to curcumin treated wounds as shown by terminal deoxynucleotidyl transferase–mediated deoxyuridyl triphosphate nick end labeling analysis. Curcumin was effective both orally and topically. These results show that curcumin enhanced wound repair in diabetic impaired healing, and could be developed as a pharmacological agent in such clinical settings.


Nature Communications | 2015

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

Nikolaos Patsoukis; Kankana Bardhan; Pranam Chatterjee; Duygu Sari; Bianling Liu; Lauren N. Bell; Edward D. Karoly; Gordon J. Freeman; Victoria Petkova; Pankaj Seth; Lequn Li; Vassiliki A. Boussiotis

During activation, T cells undergo metabolic reprogramming, which imprints distinct functional fates. We determined that on PD-1 ligation, activated T cells are unable to engage in glycolysis or amino acid metabolism but have an increased rate of fatty acid β-oxidation (FAO). PD-1 promotes FAO of endogenous lipids by increasing expression of CPT1A, and inducing lipolysis as indicated by elevation of the lipase ATGL, the lipolysis marker glycerol and release of fatty acids. Conversely, CTLA-4 inhibits glycolysis without augmenting FAO, suggesting that CTLA-4 sustains the metabolic profile of non-activated cells. Because T cells utilize glycolysis during differentiation to effectors, our findings reveal a metabolic mechanism responsible for PD-1-mediated blockade of T-effector cell differentiation. The enhancement of FAO provides a mechanistic explanation for the longevity of T cells receiving PD-1 signals in patients with chronic infections and cancer, and for their capacity to be reinvigorated by PD-1 blockade.


Molecular Cancer Therapeutics | 2009

LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer

Han Xie; Vladimir A. Valera; Maria J. Merino; Angela M. Amato; Sabina Signoretti; William M. Linehan; Vikas P. Sukhatme; Pankaj Seth

The genetic basis for the hereditary leiomyomatosis and renal cell cancer syndrome is germ-line inactivating mutation in the gene for the Krebs/tricarboxylic acid cycle enzyme, fumarate hydratase (FH), the enzyme that converts fumarate to malate. These individuals are predisposed to development of leiomyomas of the skin and uterus as well as highly aggressive kidney cancers. Inhibition of FH should result in significant decrease in oxidative phosphorylation necessitating that glycolysis followed by fermentation of pyruvate to lactate will be required to provide adequate ATP as well as to regenerate NAD+. Moreover, FH deficiency is known to up-regulate expression of hypoxia-inducible factor (HIF)-1α by enhancing the stability of HIF transcript. This leads to activation of various HIF-regulated genes including vascular endothelial growth factor and glucose transporter GLUT1 and increased expression of several glycolytic enzymes. Because lactate dehydrogenase-A (LDH-A), also a HIF-1α target, promotes fermentative glycolysis (conversion of pyruvate to lactate), a step essential for regenerating NAD+, we asked whether FH-deficient cells would be exquisitely sensitive to LDH-A blockade. Here, we report that hereditary leiomyomatosis and renal cell cancer tumors indeed overexpress LDH-A, that LDH-A inhibition results in increased apoptosis in a cell with FH deficiency and that this effect is reactive oxygen species mediated, and that LDH-A knockdown in the background of FH knockdown results in significant reduction in tumor growth in a xenograft mouse model. [Mol Cancer Ther 2009;8(3):626–35]


Brain Research Bulletin | 2007

Modulation of interleukin-1β mediated inflammatory response in human astrocytes by flavonoids: Implications in neuroprotection

Vivek Sharma; Mamata Mishra; Soumya Ghosh; Richa Tewari; Anirban Basu; Pankaj Seth; Ellora Sen

The proinflammatory cytokine interleukin-1beta (IL-1beta) contributes to inflammation and neuronal death in CNS injuries and neurodegenerative pathologies, and astrocytes have been implicated as the primary mediators of IL-1beta induced neuronal death. As astrocytes play an important role in supporting the survival and functions of neurons, we investigated the effect of plant flavonoids quercetin and luteolin, with known anti-inflammatory properties in modulating the response of human astrocytes to IL-1beta for therapeutic intervention. Flavonoids significantly decreased the release of reactive oxygen species (ROS) from astrocytes stimulated with IL-1beta. This decrease was accompanied by an increase in expression of superoxide dismutase (SOD-1) and thioredoxin (TRX1)-mediators associated with protection against oxidative stress. Flavonoids not only modulated the expression of astrocytes specific molecules such as glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), and ceruloplasmin (CP) both in the presence and absence of IL-1beta but also decreased the elevated levels of proinflammatory cytokine interleukin-6 (IL-6) and chemokines interleukin-8 (IL-8), interferon-inducible protein (IP-10), monocyte-chemoattractant protein-1 (MCP-1), and RANTES from IL-1beta activated astrocytes. Significant decrease in neuronal apoptosis was observed in neurons cultured in conditioned medium obtained from astrocytes treated with a combination of IL-1beta and flavonoids as compared to that treated with IL-1beta alone. Our result suggests that by (i) enhancing the potential of activated astrocytes to detoxify free radical, (ii) reducing the expression of proinflammatory cytokines and chemokines, and (iii) modulating expression of mediators associated with enhanced physiological activity of astrocyte in response to injury, flavonoids confer (iv) protection against IL-1beta induced astrocyte mediated neuronal damage.


Proceedings of the National Academy of Sciences of the United States of America | 2001

HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells

Ian E. Krop; Dennis C. Sgroi; Dale Porter; Kathryn L. Lunetta; Rebbecca LeVangie; Pankaj Seth; Carolyn M. Kaelin; Esther Rhei; Marcus Bosenberg; Stuart J. Schnitt; Jeffrey R. Marks; Zrinka Pagon; Drazen Belina; Jasminka Razumovic; Kornelia Polyak

To identify molecular alterations implicated in the initiating steps of breast tumorogenesis, we compared the gene expression profiles of normal and ductal carcinoma in situ (DCIS) mammary epithelial cells by using serial analysis of gene expression (SAGE). Through the pair-wise comparison of normal and DCIS SAGE libraries, we identified several differentially expressed genes. Here, we report the characterization of one of these genes, HIN-1 (high in normal-1). HIN-1 expression is significantly down regulated in 94% of human breast carcinomas and in 95% of preinvasive lesions, such as ductal and lobular carcinoma in situ. This decrease in HIN-1 expression is accompanied by hypermethylation of its promoter in the majority of breast cancer cell lines (>90%) and primary tumors (74%). HIN-1 is a putative cytokine with no significant homology to known proteins. Reintroduction of HIN-1 into breast cancer cells inhibits cell growth. These results indicate that HIN-1 is a candidate tumor suppressor gene that is inactivated at high frequency in the earliest stages of breast tumorogenesis.


Journal of Immunology | 2013

Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells

Zaheed Husain; Yannu Huang; Pankaj Seth; Vikas P. Sukhatme

In this study, we explore the hypothesis that enhanced production of lactate by tumor cells, because of high glycolytic activity, results in inhibition of host immune response to tumor cells. Lactate dehydrogenase-A (LDH-A), responsible for conversion of pyruvate to lactate, is highly expressed in tumor cells. Lentiviral vector–mediated LDH-A short hairpin RNA knockdown Pan02 pancreatic cancer cells injected in C57BL/6 mice developed smaller tumors than mice injected with Pan02 cells. A decrease occurred in the frequency of myeloid-derived suppressor cells (MDSCs) in the spleens of mice carrying LDH-A–depleted tumors. NK cells from LDH-A–depleted tumors had improved cytolytic function. Exogenous lactate increased the frequency of MDSCs generated from mouse bone marrow cells with GM-CSF and IL-6 in vitro. Lactate pretreatment of NK cells in vitro inhibited cytolytic function of both human and mouse NK cells. This reduction of NK cytotoxic activity was accompanied by lower expression of perforin and granzyme in NK cells. The expression of NKp46 was decreased in lactate-treated NK cells. These studies strongly suggest that tumor-derived lactate inhibits NK cell function via direct inhibition of cytolytic function as well as indirectly by increasing the numbers of MDSCs that inhibit NK cytotoxicity. Depletion of glucose levels using a ketogenic diet to lower lactate production by glycolytic tumors resulted in smaller tumors, decreased MDSC frequency, and improved antitumor immune response. These studies provide evidence for an immunosuppressive role of tumor-derived lactate in inhibiting innate immune response against developing tumors via regulation of MDSC and NK cell activity.


Genome Biology | 2013

Modeling precision treatment of breast cancer

Anneleen Daemen; Obi L. Griffith; Laura M. Heiser; Nicholas Wang; Oana M Enache; Zachary Sanborn; Francois Pepin; Steffen Durinck; James E. Korkola; Malachi Griffith; Joe S Hur; Nam Huh; Jong-Suk Chung; Leslie Cope; Mary Jo Fackler; Christopher B. Umbricht; Saraswati Sukumar; Pankaj Seth; Vikas P. Sukhatme; Lakshmi Jakkula; Yiling Lu; Gordon B. Mills; Raymond J. Cho; Eric A. Collisson; Laura J. van 't Veer; Paul T. Spellman; Joe W. Gray

BackgroundFirst-generation molecular profiles for human breast cancers have enabled the identification of features that can predict therapeutic response; however, little is known about how the various data types can best be combined to yield optimal predictors. Collections of breast cancer cell lines mirror many aspects of breast cancer molecular pathobiology, and measurements of their omic and biological therapeutic responses are well-suited for development of strategies to identify the most predictive molecular feature sets.ResultsWe used least squares-support vector machines and random forest algorithms to identify molecular features associated with responses of a collection of 70 breast cancer cell lines to 90 experimental or approved therapeutic agents. The datasets analyzed included measurements of copy number aberrations, mutations, gene and isoform expression, promoter methylation and protein expression. Transcriptional subtype contributed strongly to response predictors for 25% of compounds, and adding other molecular data types improved prediction for 65%. No single molecular dataset consistently out-performed the others, suggesting that therapeutic response is mediated at multiple levels in the genome. Response predictors were developed and applied to TCGA data, and were found to be present in subsets of those patient samples.ConclusionsThese results suggest that matching patients to treatments based on transcriptional subtype will improve response rates, and inclusion of additional features from other profiling data types may provide additional benefit. Further, we suggest a systems biology strategy for guiding clinical trials so that patient cohorts most likely to respond to new therapies may be more efficiently identified.


Proceedings of the National Academy of Sciences of the United States of America | 2003

A neural survival factor is a candidate oncogene in breast cancer

Dale Porter; Stanislawa Weremowicz; Koei Chin; Pankaj Seth; Aparna Keshaviah; Jaana Lahti-Domenici; Young Kyung Bae; Constance L. Monitto; Ana Merlos-Suarez; Jennifer A. Chan; Christine M. Hulette; Andrea L. Richardson; Cynthia C. Morton; Jeffrey R. Marks; Mabel P. Duyao; Ralph H. Hruban; Edward Gabrielson; Rebecca Gelman; Kornelia Polyak

Using serial analysis of gene expression (SAGE), we identified a SAGE tag that was present only in invasive breast carcinomas and their lymph node metastases. The transcript corresponding to this SAGE tag, dermcidin (DCD), encodes a secreted protein normally expressed only in the pons of the brain and sweat glands. Array comparative genomic hybridization, fluorescence in situ hybridization, and immunohistochemical analyses determined that DCD is overexpressed in ≈10% of invasive breast carcinomas; in some cases its overexpression is coupled with a focal copy number gain of its locus at 12q13.1, and its expression is associated with advanced clinical stage and poor prognosis. Expression of DCD in breast cancer cells promotes cell growth and survival and reduces serum dependency. Putative high- and low-affinity receptors for DCD are present on the cell surface of breast carcinomas and neurons of the brain. Based on these data we hypothesize that DCD may play a role in tumorigenesis by means of enhancing cell growth and survival in a subset of breast carcinomas.


Annals of Neurology | 2008

Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif

Mamata Mishra; S. Vetrivel; Nagadenahalli B. Siddappa; Udaykumar Ranga; Pankaj Seth

Human immunodeficiency virus‐1 (HIV‐1) causes mild to severe cognitive impairment and dementia. The transactivator viral protein, Tat, is implicated in neuronal death responsible for neurological deficits. Several clades of HIV‐1 are unequally distributed globally, of which HIV‐1 B and C together account for the majority of the viral infections. HIV‐1–related neurological deficits appear to be most common in clade B, but not clade C prevalent areas. Whether clade‐specific differences translate to varied neuropathogenesis is not known, and this uncertainty warrants an immediate investigation into neurotoxicity on human neurons of Tat derived from different viral clades

Collaboration


Dive into the Pankaj Seth's collaboration.

Top Co-Authors

Avatar

Vikas P. Sukhatme

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Radha K. Maheshwari

Uniformed Services University of the Health Sciences

View shared research outputs
Top Co-Authors

Avatar

Jun-ichi Hanai

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mamata Mishra

National Brain Research Centre

View shared research outputs
Top Co-Authors

Avatar

Dinesh K. Kulshreshtha

Central Drug Research Institute

View shared research outputs
Top Co-Authors

Avatar

Anoop K. Singh

Uniformed Services University of the Health Sciences

View shared research outputs
Top Co-Authors

Avatar

Eugene O. Major

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Gurmel S. Sidhu

Uniformed Services University of the Health Sciences

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge